Page 2 - Morphosys Group Key Figures News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results

MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Rheinland pfalzUnited statesSan diegoJean paul kressThomas biegiJulia neugebauerEamonn nolanMonjuvi minjuviXencor incExchange commissionShare of loss associatesLymphoma societyDrug administrationAmerican society of hematologyMorphosys group key figuresDevelopment rd expenses

MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results

MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomGeorge golumbeskiJean paul kressJulia neugebauerMonjuvi minjuviThomas biegiEamonn nolanMichael brosnanExchange commissionAmerican society of clinical oncologyXencor incShare of loss associatesMorphosys group key figuresJanssen biotech incEuropean hematology association

MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results

MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomMichael brosnanMonjuvi minjuviGeorge golumbeskiJean paul kressShare of loss associatesJanssen biotech incXencor incEuropean hematology associationDrug administrationInternational conference on malignant lymphomaAmerican society of clinical oncologyDevelopment rd expensesMorphosys group key figuresCompany supervisory board

MorphoSys AG Reports First Quarter 2023 Financial Results

Monjuvi U.S. net product sales of US$ 20.8 million (€ 19.4 million) for the first quarter of 2023 Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline

United statesUnited kingdomCharlotte lohmannJean paul kressThomas biegiLucinda crabtreeMonjuvi minjuviJulia neugebauerEamonn nolanAmerican association for cancer researchJanssen biotech incMorphosys group key figuresExchange commissionDrug administrationAmerican society of clinical oncologyShare of loss associates

EQS-News: MorphoSys AG Reports First Quarter 2023 Financial Results

EQS-News: MorphoSys AG / Key word(s): Quarterly / Interim Statement MorphoSys AG Reports First Quarter 2023 Financial Results .

United kingdomUnited statesJean paul kressLucinda crabtreeCharlotte lohmannEamonn nolanThomas biegiMonjuvi minjuviJulia neugebauerAmerican society of clinical oncologyShare of loss associatesXencor incMorphosys group key figuresJanssen biotech incAmerican association for cancer researchDevelopment rd expenses